StemCell Therapy

Type 2 diabetes is a common condition in the UK and causes the body not to respond to insulin properly, so it doesn't produce enough. This causes a persons blood sugar levels to become too high. If blood sugar levels arent controlled and stay too high it can lead to a number of problems, including kidney failure, nerve damage, heart disease and stroke, so its important to make lifestyle changes to help keep blood sugar in check.

Regularly eating a poor diet can increase a persons risk of developing type 2 diabetes, so making changes to what you eat is advised.

Experts say theres nothing you cannot eat if you have type 2 diabetes, but certain foods should be limited.

The NHS says you should: Eat a wide range of foods - including fruit, vegetables and some starchy foods like pasta, keep sugar fat and salt to a minimum, and eat breakfast, lunch and dinner every day - do not skip meals.

But individual food and drink have also been proven to have blood sugar lowering qualities, and when it comes to the first meal of the day, breakfast, a certain fruit has been shown to have a positive effect on blood sugar levels.

READ MORE:Type 2 diabetes: Adding this superfood to your breakfast could lower your blood sugar

A 2003 animal study showed fig extract can contribute to diabetes treatment by normalising blood fatty acid and vitamin E levels.

But this isnt the only part of the fig plant proven to help blood sugar levels.

A 2016 study in rats showed ficusin, an extract from fig leaves, improves insulin sensitivity and has other antidiabetic properties.

Some people may be sceptical over eating fruit because of its sugar content, but the sugar in whole fruit does not count towards free sugars, so it is not this type of sugar we need to cut down on, explains Diabetes UK.

DON'T MISS

The charity explains: This is different to the free sugar in drinks, chocolate, cakes and biscuits, as well as in fruit juices and honey.

Its the amount of carbohydrate you eat that has the biggest effect on blood sugar levels after eating, says the charity.

It continues: A portion of fruit, such as a medium apple, generally contains about 15 to 20g carbs.

It is better to reduce your intake of chocolate, sugary drinks, cakes and other snacks than whole fruit when trying to restrict your carb intake to help manage your blood glucose levels.

Figs could be enjoyed on top of a bowl of oatmeal, which has also been proven to have a positive impact on blood sugar levels.

Oatmeal contains a soluble fibre called beta-glucan that can help improve insulin response and possible reduce blood sugar too.

A review of research on the benefits of oatmeal for people with type 2 diabetes found oatmeal has a positive effect on a blood sugar control.

Alongside eating healthily, being active can help lower blood sugar levels.

Here is the original post:
Type 2 diabetes: The 50p fruit you could eat for breakfast to lower blood sugar - Express

Animal sociability through microbes

Accumulating evidence suggests that the microbiota living in and on animals has important functions in the social architecture of those animals. Sherwin et al. review how the microbiota might facilitate neurodevelopment, help program social behaviors, and facilitate communication in various animal species, including humans. Understanding the complex relationship between microbiota and animal sociability may also identify avenues for treating social disorders in humans.

Science, this issue p. eaar2016

Increasingly, it is recognized that the microbes resident in the gastrointestinal tract can influence brain physiology and behavior. Research has shown that the gastrointestinal microbiota can signal to the brain via a diverse set of pathways, including immune activation, production of microbial metabolites and peptides, activation of the vagus nerve, and production of various neurotransmitters and neuromodulators in the gut itself. Collectively, this bidirectional pathway is known as the microbiota-gut-brain axis. In the absence of a microbiota, germ-free and antibiotic-treated mice exhibit alterations to several central physiological processes such as neurotransmitter turnover, neuroinflammation, neurogenesis, and neuronal morphology. Perhaps as a result of these neurological alterations, the behavior of rodents lacking a microbiotaespecially social behavioris remarkably different from that of rodents colonized with bacteria. Conversely, supplementation of animals with certain beneficial live bacteria (e.g., Bifidobacterium and Lactobacillus) can lead to notable improvements in social behavior both in early life and in adulthood. Collectively, these results suggest that microbial signals are important for healthy neurodevelopment and programming of social behaviors in the brain. Although research on the functional and ecological implications of the gut microbiota in natural populations is growing, from an evolutionary perspective it remains unclear why and when relationships between microbes and the social brain arose. We propose that a trans-species analysis may aid in our understanding of human sociability.

Sociability comprises a complex range of interactive behaviors that can be cooperative, neutral, or antagonistic. Across the animal kingdom, the level of sociability an animal displays is variable; some are highly social (e.g., primates, termites, and honey bees), living within cooperative communities, whereas others have a mostly solitary existence (e.g., bears). Consequently, although studies on germ-free and antibiotic-treated animals have yielded insights into how the microbiota may influence social behaviors, they are perhaps too reductionist to fully appreciate the complex relationship between symbiotic bacteria in the gastrointestinal tract and host sociability when considering a broader zoological perspective. Some social interactions have evolved to facilitate horizontal transmission of microbiota. Observations across both invertebrate and vertebrate species suggest that factors such as diet and immunity generate selection pressures that drive the relationship between microbiota and social behavior. Although microbiota may influence behaviors endogenously through regulation of the gut-brain axis, some animal species may have evolved to use symbiotic bacteria exogenously to mediate communication between members of the same species. Hyenas, for example, produce an odorous paste from their scent glands that contains fermentative bacteria that is suggested to facilitate social cohesion among conspecifics. This complex relationship between animals and microbiota raises the hypothesis that microbes may have influenced the evolution of the social brain and behavior as a means to propagate their own genetic material.

Understanding the factors that affect the development and programming of social behaviors across the animal kingdom is important not only in terms of rethinking the evolution of brain physiology and behavior, but also in terms of providing greater insight into disorders of the social brain in humans [including autism spectrum disorders (ASDs), social phobia, and schizophrenia]. Evidence for a link between the microbiota and these conditions is growing, and preclinical and emerging clinical data raise the hypothesis that targeting the microbiota through dietary or live biotherapeutic interventions can improve the associated behavioral symptoms in such neurodevelopmental disorders. Larger clinical trials are required to confirm the efficacy of such interventions before they are recognized as a first-line treatment for neurodevelopmental disorders. Although such connections between gut bacteria and neurodevelopmental disorders are currently an intriguing area of research, any role for the microbiota in the evolution of social behaviors in animals does not supersede other contributing factors. Rather, it adds an additional perspective on how these complex behaviors arose.

The bidirectional pathway between the gut microbiota and the central nervous system, the microbiota-gut-brain axis, influences various complex aspects of social behavior across the animal kingdom. Some animals have evolved their own unique relationship with their gut microbiota that may assist them in interacting with conspecifics. The relationship between the gut microbiota and social behavior may help to explain social deficits observed in conditions such as autism spectrum disorders (ASDs) and could potentially lead to the development of new therapies for such conditions.

Sociability can facilitate mutually beneficial outcomes such as division of labor, cooperative care, and increased immunity, but sociability can also promote negative outcomes, including aggression and coercion. Accumulating evidence suggests that symbiotic microorganisms, specifically the microbiota that reside within the gastrointestinal system, may influence neurodevelopment and programming of social behaviors across diverse animal species. This relationship between host and microbes hints that host-microbiota interactions may have influenced the evolution of social behaviors. Indeed, the gastrointestinal microbiota is used by certain species as a means to facilitate communication among conspecifics. Further understanding of how microbiota influence the brain in nature may be helpful for elucidating the causal mechanisms underlying sociability and for generating new therapeutic strategies for social disorders in humans, such as autism spectrum disorders (ASDs).

Read more here:
Microbiota and the social brain - Science Magazine

SALT LAKE CITY When she was 8 years old, Mary was writing about diets in her journal. She did Optifast like Oprah Winfrey. She was always eating too much or eating too little, always thinking about what she was eating and what the scale said.

Only as a mom in her 40s was she able to stop obsessing about her weight, after having surgery that removed 80% of her stomach.

Surgery, for me, has really been a blessing, physically and emotionally. I feel free from the physical and emotional burden that I felt when I weighed so much more, the Utah mom said.

Thats why Mary was willing to consider bariatric surgery for her children when they, too, became extremely overweight. Four of her seven children have had their digestive system reordered, severely restricting what and how much they eat and drink.

The surgery is controversial and only rarely performed on minors, but that could change now that the leading group of pediatricians has issued a policy statement urging more access to metabolic and bariatric surgery for adolescents.

In a report released Sunday, the American Academy of Pediatrics said age should not be a barrier to surgery for a child with extreme obesity and that insurance companies should cover the procedure.

Although behavioral and lifestyle interventions will be successful for certain individuals, the overall outcomes of behavioral and lifestyle interventions are discouraging when viewed as a solution for a larger number of patients with severe obesity. Youth with severe obesity require effective intervention to prevent a lifetime of illness and poor quality of life, the AAP statement said.

Mary, who did not want to be identified because of potential problems with health insurance coverage, said that parents of extremely overweight adolescents should consider weight loss surgery if the child wants it, even though the procedure is rarely covered by insurance and can cost upwards of $10,000. She wishes shed had the option when she was a child and believes it would have radically changed her life for the better.

Think about how many parents are willing to shell out big bucks for braces, and thats primarily a cosmetic thing, Mary said. This is someones health. This is their longevity.

Goodbye, soda pop

Weight loss surgery has lifelong implications, but so does obesity.

Obesity is associated with cardiovascular disease, Type 2 diabetes, sleep apnea, fatty liver disease and gastroesophageal reflux disease, among others. It is also increasingly implicated in 12 types of cancer.

And the number of American children with severe obesity has nearly doubled since 1999. Nearly 10% of 12- to 15-year-olds have obesity, and 14% of 16- to 19-year-olds do.

Even in Utah, where childhood obesity rates are historically among the lowest in the nation, obesity is increasing, said Dr. Eric Volckmann, director of the University of Utah Health Care Bariatric Surgery Program in Salt Lake City.

While behavioral changes can provide moderate, short-term success for young children and those at lower weights, for children whose obesity is severe, metabolic changes make it more difficult to lose weight and to keep it off, the AAP said.

There are a variety of ways to alter the digestive system so that people dont overeat. The most common are the gastric bypass, sleeve gastrectomy, adjustable gastric band and biliopancreatic diversion with duodenal switch, according to the American Society for Metabolic and Bariatric Surgery.

Most people will have to make changes beyond how much they eat, however. For example, carbonated beverages can cause discomfort after some types of surgery, which means soda pop is history. Alcohol potency goes up by 300% in people who have had a gastric bypass. And most people will have to take vitamins and supplements for the rest of their lives, lest they become severely malnourished.

Anyone considering weight loss surgery needs to understand that the surgeries are just a tool and they all require patients to make dietary changes and lifestyle modifications to be successful and to maintain weight loss. None of the operations are a quick fix, Volckmann said.

The surgery is controversial for adults and rare among children or teens. The American Society for Metabolic and Bariatric Surgery says that of 227,000 procedures performed by its member surgeons in 2017, only about 300 involved people under the age of 18.

Dr. Daniel Cottam of the Bariatric Medicine Institute in Salt Lake City said he operates on a dozen or fewer teens every year.

Bariatric surgery appears to be a valuable tool in treatment of obesity, Dr. Jacob M. Appel, an assistant professor and director of ethics education in psychiatry at Icahn School of Medicine at Mount Sinai in New York City, said in an email. But, he added, It is only one tool in that arsenal. which should also include efforts at the societal level to improve the food environment for children and to address the nutritional deserts in which many low-income children are forced to live.

Are parents to blame?

Had she not had the surgery herself, Mary said she probably would never have considered it as an option for her children, even when several of them became more than 100 pounds overweight.

I spent so many decades of my life dieting and trying to lose weight and feeling like a failure every time the weight came back on. It has been refreshing for me to be free of that constant pressure I put on myself, she said.

Mary said she knows that some people will judge her parenting and blame her for what she fed her children when they were young. But she notes that many nutrition scientists have come to realize that her generation, and her parents, were given bad information about what comprises a healthy diet. And Mary said that her family is prone to gaining weight on a high-carbohydrate diet, even if the carbohydrates are nutrient-rich.

If I could do it over, I wouldnt have followed the food pyramid, which has so much focus on bread and rice and cereal and grain, she said. We are very carb-sensitive; we dont process carbs like most people do.

While some people still believe obesity is caused by a sedentary lifestyle and poor food choices, that hasnt been the position of the American Medical Association since 2003, when the AMA declared obesity a disease.

Skinny people believe obesity is caused by life choices. Thats only partly true, Cottam said. Most people who become really obese, especially children, they have metabolisms that predispose them to this.

In its 2018 best-practice guidelines for pediatric surgery, the American Society for Metabolic & Bariatric Surgery said that, like cancer, obesity is a multifactorial disease caused by a combination of genetics, environment and metabolic programming. The group said that surgery shouldnt be a treatment of last resort but should be readily offered to adolescents who are extremely obese.

In its new policy statement, the AAP said that its recommendations are for adolescents between the ages of 13 and 18 whose body mass index is 35 or greater, or a BMI that is 120% or greater of the 95th percentile for their age and sex.

Appel, the author of a new book on medical ethics, Who Says Youre Dead?, said all elective surgery should be approached with care, especially when children and adolescents are involved.

At a minimum, minors should assent to the surgery and be given sufficient time to reflect upon the decision and its implications. At the same time, delay until the age of majority while appropriate for some conditions may not be suitable here, he said.

Extreme obesity has both physical and psychological implications for many youths that cannot be reversed by surgery as adults, so pushing off interventions until the age of majority is often not in the best interests of the child or teen.

Safer than gallbladder surgery

No matter how effective, surgery of any kind comes with risk.

Death resulting from weight loss surgery is extremely rare; one study published in 2011 found 18 deaths within 30 days of bariatric surgery among 6,118 patients, despite the fact that bariatric surgical patients are virtually by definition high risk surgical candidates.

A study of 60,000 patients from physicians affiliated with the ASMBS had even lower one-month mortality rates: one out of 1,000 patients, or 0.13%.

This rate is considerably less than most other operations, including gallbladder and hip replacement surgery, the society says on its website.

But there are other risks, among them, a greater chance of developing an alcohol abuse disorder because the body develops a greater sensitivity to alcohol and some procedures result in higher levels of blood alcohol compared to people who have not had the procedure. Girls who have metabolic and bariatric surgery have a higher risk for pregnancy than their peers and may be at risk for complications during pregnancy and premature birth.

Some people report depression or sadness after having the procedure, and two studies have shown a small but significant increase in suicide.

The writer Roxane Gay, who had a sleeve gastrectomy in 2018, wrote about the experience, saying she was depressed and miserable.

Gay said that it is maddening that she can only eat tiny portions of the food that used to bring her comfort. After a few bites of anything, the discomfort begins, and then that discomfort evolves into pain, she wrote.

Besides the physical changes that weight loss surgery brings, it also shuts off or restricts a major source of human pleasure. That is one reason that Paige Fieldsted, a mother of two in Taylorsville, Utah, said that she has not seriously considered weight loss surgery and wouldnt have wanted it as a teen, even though she has struggled with weight issues since she was a child.

Food is very much for me, and for most people, a connector. Holidays center around food, and I want to be able to enjoy it, said Fieldsted, the author of Confessions From Your Fat Friend.

I understand what its like to be the biggest one in the room, to feel like the only way that things are going to get better for you is to get skinny. But I can also tell you from experience that thats not true, she said.

Mary also agreed that its important that parents of children with obesity focus on the positive things about their children and not just their weight. I wish I had focused more on their worth and self-esteem, all the great things about them. You have to be sure that they know you love them for who they are, that your love is not dependent on their weight.

Concerns about how a person will adapt to life-altering surgery is one reason that the American Academy of Pediatrics and most surgeons require an extensive period of preparation, especially for young patients. A comprehensive evaluation by a behavioral health clinician is essential early in the process to document the childs psychological well-being and to to assure that the child has the necessary social and emotional support to follow through with required postoperative lifestyle modifications.

No regrets

Despite the risks she and her children assumed, Mary said her family has no regrets about having had the surgery, which Mary and her husband paid for out-of-pocket. While she has not kept the surgery a secret from close family members and friends, she does not want to be publicly identified because of the possibility that her health insurance companies might not pay for any future complications that they might say were connected to the surgery, which they do not cover.

The possibility of complications is one reason that Volckmann in Salt Lake City warns people not to seek bariatric surgery for themselves or their children out of the country.

One adult from Utah died earlier this year after undergoing bariatric surgery in Mexico, and eight others were sickened by bacteria. But back at home, even minor complications will likely not be covered by any insurer who did not cover the initial surgery, Volckmann said. I would not allow a relative to have any type of surgical procedure where complications from that procedure werent covered. The financial risks would be too high. I dont think people understand that when they go to Mexico, he said, adding that he knows people who have had to declare bankruptcy because of medical bills stemming from complications from surgery.

The growth of medical tourism underscores the need for insurance companies to provide coverage for weight loss surgery, as the AAP recommends, he said. While the University Hospital does not offer bariatric surgery for anyone under the age of 18, he believes that if done in a well-developed program and done properly, it is appropriate to offer.

Its probably not for all adolescents, but its appropriate for some.

Volckmann said that insurance companies have resisted paying for weight loss surgery in part because there is no immediate benefit to them; a child will likely be off her parents policy before there is any payoff in improved health and lowered costs. But for society as a whole, there is a great return in terms of medical problems that can develop over time, Volckmann said.

At the Bariatric Medicine Institute, Cottam, too, expressed frustration with the lack of coverage. Why would you cover someones heart attack and not cover something that would prevent someones heart attack?

Mary, meanwhile, is happy with her choice to have surgery and to allow her children to do so. She notes, however, that her children were teenagers at the time of their surgery, and they made the decision without pressure from her.

Thats important for any family, she said.

If your child doesnt feel good about it, dont do it. But if the child is really wanting it and is determined and responsible and can be compliant, then I think that it can be a great blessing, she said.

Mary said that sometimes she will hear people making jokes about overweight people, and she sees it as a teachable moment. She will get out her phone and show them pictures of herself 110 pounds heavier. Despite the fact that she cant eat much without getting uncomfortable, shes comfortable now in ways she never was before. Never an athlete, she now hikes, runs and rappels.

Its not for everyone. I know people whose weight doesnt bother them, she said. But if I could have had that surgery as a teenager, I would have jumped at the chance.

View original post here:
The pros and cons of weight loss surgery for children - Deseret News

INTERVALE The Miranda Leavitt Diabetes Fund and the Conway Area Lions Club are hosting a Diabetes Awareness Event on Saturday, Nov. 16, from 10 a.m.-1 p.m. at the Miranda Diabetes Care Center, located at 3 N.H. Route 16 A in Intervale.

This free event will offer diabetes risk assessments, education on the link between diabetes and vision loss, blood glucose screening, blood pressure checks, plus information on diabetes prevention, nutrition advice and more.

Diabetes nurse practitioner Justine Fierman from the Miranda Diabetes Care Center and registered dietitian Brenda McKay from Memorial Hospital will be there to educate the community in the proper management of diabetes symptoms, and how many can decrease their risk in developing Type 2 Diabetes.

With November as National Diabetes Awareness Month, Conway Area Lions Club zone chair Linda Rafferty felt it was the right time to support an event around diabetes and vision loss.

The Conway Area Lions Club is a longtime supporter of the Miranda Leavitt Diabetes Fund and is known internationally for its work to improve health issues.

We are tackling tough problems like blindness and drug abuse as well as diabetes awareness and finding help and training for the deaf, disabled, underprivileged and the elderly. Whatever the community needs to make life better, were there to help, Rafferty said.

Rafferty said the event fits well into the Lions mission and supports a service project she personally is spearheading in her zone, which includes Lions Clubs in Laconia/Guilford, Moultonboro, Wolfeboro, Wakefield, Whittier, Meredith and Conway area.

I have chosen to spread diabetes awareness to all. This illness has affected some of my own family and friends and continues to strike many people. I was fortunate enough to meet with Brenda Leavitt and Justine Fierman from the Diabetes Care Center to work together on this project.

According to the American Diabetes Association, diabetes causes eye problems and may lead to blindness. People with diabetes do have a higher risk of blindness than people without diabetes. However, with regular checkups, most people with diabetes can keep minor vision problems minor.

Diabetic retinopathy is a general term for all disorders of the retina caused by diabetes. Huge strides have been made in the treatment of diabetic retinopathy. The sooner retinopathy is diagnosed, the more likely these treatments will be successful. The best results occur when sight is still normal. Several factors influence whether someone develops retinopathy:

Blood sugar control.

Blood pressure levels.

How long you have had diabetes.

People who keep their blood sugar levels closer to normal are less likely to have retinopathy or to have milder forms. This is why the November 16 event will be offering free blood glucose screenings and providing risk assessment information for developing diabetes.

But high blood glucose levels are just one of the risk factors of developing diabetes.

Factors such as age, weight, smoking, gender, family history, high blood pressure, activity level and ethnicity can all be indicators that diabetes could develop. Awareness and prevention efforts, such as weight loss, healthier diet choices, managing blood pressure and quitting smoking can all reduce the risk of developing Type 2 diabetes, and symptoms including vision loss.

Brenda Leavitt, founder of the Miranda Leavitt Diabetes Fund stated, We are gearing up for National Diabetes Month and the Miranda Leavitt Diabetes Fund, along with Conway Area Lions, is sponsoring this diabetes awareness event together. This disease is growing in our state and community, so the Diabetes Fund is putting together a series of screening, and education classes to follow. We are so pleased for the support from the Conway Area Lions Club and thank them for working with us on this event.

The U.S. Centers for Disease Control and Prevention reports that the number of Americans with diabetes continues to rise, with over 12 percent of the adult population estimated to have the disease, and more than a third of those aged 20 and over in the U.S. now thought to have prediabetes.

The Miranda Leavitt Diabetes Fund was founded in 2009 with a mission to provide resources, education and awareness for people with diabetes in the Mt. Washington Valley community. Miranda Leavitt passed away from complications of Type 1 Diabetes in 2007, and her parents, Rich and Brenda Leavitt, have tirelessly sought to raise funds and provide outreach around diabetes care and prevention.

The event takes place in the new location of the Miranda Diabetes Care Center in Intervale, NH. It is located at the intersection of Routes 16 and 16A. It is the practice of certified diabetes educator and nurse practitioner Justine Fierman. Fierman specializes in intensive diabetes management, insulin pump therapy, diabetes technologies, diabetes in pregnancy and continuous glucose monitoring.

For information on the Miranda Fund, go to Facebook page MLDFund. For more information on the Conway Area Lions, go to conwayarealions.org.

More:
Diabetes fund teams with Lions for awareness event - Conway Daily Sun

According to the CDC in the recent season, about 30% of adults in the hospital for the flu had diabetes.

The fact is people with diabetes, even if well-managed are at a higher risk of serious influenza complications.

According to the Director of Education and Patient Care at UHC, Brenda Conch these complications can result in hospitalization and sometimes even death.

"If they have diabetes specifically when they get the flu their diabetes is now out of control because that's what happens when an individual is ill, their glucose goes up," said Conch.

The reason those with diabetes or other chronic illnesses can get sicker from the flu is because their body is already fighting an illness.

"Your body is attending to that illness, so it doesn't really pay attention to something else coming at it," said Conch.

Conch says the flu shot is our best defense against the flu.

"Obviously the other ones is good hand hygiene and make certain you, but the best is through the flu vaccine," said Conch.

If someone with diabetes wants to get the influenza vaccine, it is recommended they must get the actual shot. Not the intranasal form because that can give you a minor case of the flu.

Obviously there are some misconceptions about the flu shot and how it works.

"Back in the old days it was a live virus, so there are people that still recall they got a shot a long time ago and they did get the flu with it. When you lived that it's hard to convince someone that is not how it is anymore. It does work, and it does work against flu we're immunizing for," said Conch.

Conch says there is an exception to every rule, but pretty much everyone needs to get the flu shot. The exception being infants or if your doctor tells you otherwise.

In addition, after an individual receives the flu shot it takes 14 days to take full effect.

See the article here:
Those with Diabetes are at greater risk for the flu and flu complications - WDTV

How the changes impacted her life and health

The pounds dropped off of Snita, losing three stone to weigh in now at eight stone. To top it off, Snita received her blood test results shortly before her 50th birthday which revealed she was no longer within the diabetic range.

Snita now considers herself a running addict and regularly runs 5ks, 10ks and half marathons. Later this year, she will take part in the iconic Simplyhealth Great South Run, part of a series of mass participation running events which has partnered with Diabetes UK, to encourage more people to become more active.

Snita is effusive in her praise for the impact running has had on her life and recently delivered a talk, with the help of Diabetes UK, on the life-changing effect it can have on other people living with diabetes.

The impact running has had on my life has been huge. If I hadnt joined my running club and got the support Ive had from my coach and the rest of the group I wouldnt have kept it up.

Running has really helped my diabetes by getting me fitter and forcing me to address my diet, which together have helped me diabetes enter into remission.

Snita has been running medication-free for 19 months now and as well as running the Simplyhealth Great South Run later this year, has also recently completed half marathons in London, Liverpool and Dublin.

She feels happier, fitter and healthier now than she has since her 20s and is determined to continue challenging herself. Its been a real journey which Im still on and I feel like a changed person.

I have so much energy and do so much more in a day than I ever did before. Its been truly life-changing.

More here:
Type 2 diabetes: Women puts her diabetes into remission by doing this activity - Express

Named after pioneering poet and activist Audre Lorde, Spelman College plans to establish a chair in queer studies, the first for a Historically Black College or University (HBCU), The Root reports. The position was supported by a $2 million donation from philanthropist Jon Stryker. In a statement issued to Forbes, Stryker states his donation helps to further students' education on LGBTQ rights.

"The more that people understand queer history and LGBTQ issues, the more likely they are to accept and support the LGBTQ community," Stryker said. "By empowering and educating the next generation, we can help make a future where LGBTQ people have full and equal protections under the law."

Mary Schmidt Campbell, Spelman's president, discussed the significance behind this new department.

A chaired professorship in Queer Studies enables the College to build on one of its strengths and that is the Spelmans educational inclusiveness, spearheaded by the Womens Research and Resource Center under the stellar direction of Dr. Beverly Guy-Sheftall," Campbell said. "Spelmans Womens Center has been and continues to be a pioneering leader in advancing scholarship in the area of Queer Studies. Jon Strykers generous contribution to further his commitment to LGBTQ inclusion and education will allow Spelman students to deepen their understanding around the study of sexuality and gender. We are honored to name the chair after the literary luminary and fierce activist, Audre Lorde.

Spelman College announces a $2M match from philanthropist Jon Stryker to establish an Endowed Queer Studies Chair named after poet and activist Audre Lorde. The professorship is the first-ever chair of its kind at an HBCU. https://t.co/nb7FVHEOal pic.twitter.com/fBIEfPFBdm

Spelman College (@SpelmanCollege) October 29, 2019

The news arrives two years after Spelman announced the admission of transgender women students, beginning in 2018."In adopting this admissions policy, Spelman continues its fervent belief in the power of the Spelman Sisterhood," Campbell said in a letter. "Students who choose Spelman come to our campus prepared to participate in a women's college that is academically and intellectually rigorous, and affirms its core mission as the education and development of high-achieving black women."

More:
'Yo! MTV Raps' Doctor Dre Discusses Living With Type 2 Diabetes And Partial Vision Loss - Vibe

In a previous related study conducted with a team from the University of Gothenburg in Sweden researchers also found that dietary fibres from barley kernel generates an increase of the gut bacteria Prevotella copri, which have a direct regulatory effect on blood sugar levels and help decrease the proportion of a type of gut bacteria that is considered unhealthy.

According to Diabetes UK, certain breakfast cereals can pose hidden risks for people with type 2 diabetes, as they contain free sugars. Free sugar is any sugar added to a food. Extra sugar means extra calories and eating too many calories can lead to obesity - a major risk factor associated with type 2 diabetes.

Breakfast cereals rich in free sugars include granola and cereal clusters, which, despite appearing healthy, are often full of free sugars and unhealthy fat.

As Diabetes Uk explained: When buying cereal, the best thing to do is look at the 'front of pack' label, and try to go for cereal with as many green lights as possible. But also check the ingredients list, some newer versions of granola simple have nuts added in.

See the original post:
Type 2 diabetes: Eating this cereal for breakfast could lower blood sugar - Express

ARLINGTON, Va., Oct. 30, 2019 /PRNewswire/ -- The American Diabetes Association (ADA) strongly supports the introduction of the Insulin Price Reduction Act in the United States House of Representatives. The ADA thanks Congressional Diabetes Caucus Co-Chairs Representative Diana DeGette (D-CO) and Representative Tom Reed (R-NY) for their leadership in introducing the House version of this legislation, which will lower the cost of insulin for many Americans who rely on it to stay alive. The Insulin Price Reduction Act was first introduced in the United States Senate on July 22, 2019.

For more than 7.4 million Americans, including all individuals with type 1 diabetes, insulin is a life-sustaining medication for which there is no substitute. Ballooning costs have put lifesaving insulin out of reach for an increasing number of Americans. Between 2002 and 2013, the average price of insulin nearly tripled. A 2018 ADA survey showed that individuals with diabetes who face high out-of-pocket costs are forced to make decisions about their insulin regimen that can have damaging consequences on their health. Many individuals with diabetes ration or forego insulin doses to reduce costs.

"Insulin is a matter of life and death," said LaShawn McIver, MD, MPH, Senior Vice President of Government Affairs and Advocacy. "For the many Americans who cannot afford their insulin, the consequences can be dire, including serious complications, such as cardiovascular disease, blindness, kidney disease, amputation, and even death. The American Diabetes Association applauds Representatives DeGette and Reed for their leadership in addressing this urgent issue. We urge all members of the House of Representatives to support this critical legislation and advance it through the legislative process."

The Insulin Price Reduction Act seeks to address the skyrocketing cost of insulin by encouraging insulin manufacturers to reduce the list price of all insulin products to their 2006 list price. Importantly, these lower-priced products would not be subject to health plan deductibles and would not be placed on less favorable formulary tiers. Rolling back list prices for insulin products by over a decade will make insulin more accessible for many Americans, both insured and uninsured.

The ADA continues to work diligently on the critical issue of insulin affordability. In 2016, the ADA's Board of Directors released a resolution calling on all entities in the insulin supply chain to increase transparency in insulin pricing and to ensure that no one living with diabetes is denied affordable access to insulin. The resolution also called on Congress to hold hearings with all entities in the insulin supply chain to help identify the reasons for the dramatic increases in insulin prices and to take action to ensure that all people who use insulin have affordable access to the insulin they need. The ADA's Make Insulin Affordable petition has achieved more than 487,000 signatures to date. In 2017, the ADA's Board of Directors convened an Insulin Access and Affordability Working Group, and the Working Group's findings were detailed in a white paper published in 2018 in the journal Diabetes Care. The ADA subsequently issued a public policy statement providing detailed recommendations to lawmakers. The ADA has also testified at multiple congressional hearings in 2018 and 2019 focused on the high cost of insulin. Resources are available through the ADA's call center at 1-800-DIABETES, and at InsulinHelp.org.

About the American Diabetes AssociationEvery day more than 4,000 people are newly diagnosed with diabetes in America. Nearly 115 million Americans have diabetes or prediabetes and are striving to manage their lives while living with the disease. The American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive. For nearly 80 years the ADA has been driving discovery and research to treat, manage and prevent diabetes, while working relentlessly for a cure. We help people with diabetes thrive by fighting for their rights and developing programs, advocacy and education designed to improve their quality of life. Diabetes has brought us together. What we do next will make us Connected for Life. To learn more or to get involved, visit us at diabetes.org or call 1-800-DIABETES (1-800-342-2383). Join the fight with us on Facebook (American Diabetes Association), Twitter (@AmDiabetesAssn) and Instagram (@AmDiabetesAssn).

Contact: Alex Day, 703-253-4843press@diabetes.org

See original here:
The American Diabetes Association Applauds the Insulin Price Reduction Act, Introduced Yesterday by the House Diabetes Caucus - The Breeze

(StatePoint) Two in five Medicare patients with diabetes (40.9 percent) reach the Part D coverage gap, and are responsible for the full cost of their prescription drugs.(1)To help ease this financial burden, Eli Lilly and Company offers several solutions, including insulins with a lower list price.

People with diabetes will need to make important decisions for healthcare coverage during the Medicare open enrollment period (October 15 to December 7, 2019). To help ensure treatments are affordable, its important to consider the following when choosing a Medicare coverage plan:

Make a list of important priorities including cost, coverage and network that your plan must have based on your individual health needs.

A checklist can help guide important conversations when choosing a plan. Lillys checklist can help identify different cost, coverage and network considerations specifically for people with diabetes.

When considering which plan to choose, Lillys Plan Guide can help identify which Medicare Part D plans cover the lower priced insulin in each state.

The transition to Medicare for people with diabetes can be difficult and there are many factors, such as cost, that go into making a coverage decision. Were working to ease the financial burden for the growing number of people with diabetes who are in the coverage gap phase of their plan, said Tony Ezell, vice president, U.S. Connected Care and Insulins, Lilly. The goal is that Lillys solutions will help people with diabetes access affordable insulin until long-term, systemic changes are made to the U.S. healthcare system.

Visit InsulinAffordability.com or call the Lilly Diabetes Solution Center to learn more about the solutions available that may help people with diabetes significantly decrease the amount they pay for Lilly insulin. Helpline representatives are available at (833) 808-1234 from 9 a.m. to 8 p.m. ET Monday through Friday.

PP-SP-US-0110 10/2019 (c)Lilly USA, LLC 2019. All rights reserved.

(1) American Diabetes Association. The Impact of Medicare Part D on the proportion of Out-of-Pocket Prescription Drug Costs Among Older Adults With Diabetes. Available at: https://care.diabetesjournals.org/content/40/4/502.long. Accessed October 1, 2019.

Follow this link:
Medicare and Diabetes: A Few Things to Know - Coronado Eagle and Journal

Additionally, rates of infection, mortality and readmission are 4x, 1.5x and 1.4x greater, respectively.

The question is, are we as a healthcare community doing everything we can to improve these outcomes? Are we paying enough attention to the unique needs of patients with diabetes?

The results of recent nationwide survey indicate we need to do better, and with the shift from volume to value, I would say the question becomes, can we afford not to?

Download the complete survey results here.

The truth is, managing diabetes within our inpatient populations is strife with challenges. This is a large-scale issue and the numbers are growing.

On average, one of every three hospitalized patients -- the majority with diabetes -- requires insulin to control blood glucose during their stay, a medication that although widely prescribed and absolutely necessary is inherently dangerous. Fifty percent of all medication errors involve insulin, including one-third of all fatal medication errors. Insulin is considered a high-alert medication because it has the potential to cause significant patient harm if misused.

Certainly hospitals and health systems face other patient safety challenges, but very few have as substantial an impact on both clinical and financial outcomes. Insulin therapy, whether intravenous or subcutaneous, is both complex and difficult to manage.

When insulin therapy lacks standardization and best practices are not the norm, poorly controlled blood glucose prevails, which can lead to coma, stroke, sepsis, cardiac arrest . . . even death. A recent study by AdventHealth Orlando showed that hospitalized patients who experience severe hypoglycemia (abnormally low blood glucose) incur $10,405 of excess cost per stay and a 61.5% higher readmission rate.

This toll is largely avoidable, but only if hospitals and health systems prioritize glycemic management. The results of this survey underscore there is vast room for improvement.

Download the complete survey results here.

Some of the findings that strike me as concerning include:

The good news is, improving the care of hospitalized patients with diabetes and achieving best practices in glycemic management are attainable goals, especially with the aid of purpose-built technologies such as the eGlycemic Management System.

You are welcome to arrange a complimentary consultation with a Glytec clinical executive to discuss your glycemic management needs and goals. Click here.

Dr. Rhinehart is a diabetologist and Chief Medical Officer of Glytec. He was the first U.S. physician board certified in advanced diabetes management (BC-ADM).

Read this article:
Survey reveals better care needed for hospitalized patients with diabetes - HealthLeaders Media

For kids with food allergies, dietary restrictions or Type I diabetes, Halloween trick-or-treating can put kids at risk for serious health issues.

Candies made with peanuts, eggs, and wheat and dairy products may expose children to food allergens, and sweet treats elevate blood sugar levels.

"There are ways to make (Halloween) fun even though they can't eat all the candy they collect," said Shelby Shelby, a registered dietitian with Owensboro Health.

She suggested families may want to consider inviting the "Switch Witch" to visit Halloween night. Kids lay out all the candy they've collected, and the Switch Witch comes while they sleep something like the tooth fairy to exchange the candy for money, movie tickets, trips to the zoo, gift cards or toys.

Somer Wilhite, manager of marketing at OH, has kids ages 6 and 10.

"We've already been trick-or-treating twice this week," Wilhite said.

She pays her kids $1 per 20 pieces of candy they hand over. Then, she gives away the treats. Nursing homes, hospitals and homeless shelters usually appreciate a little extra candy, she said.

Shelby participates in the Teal Pumpkin Project, a national effort to make Halloween safe and happy for all kids. Homeowners paint a pumpkin teal and put it on the front porch to indicate they give nonfood treats, such as boxes of crayons, bubbles, whistles, glow sticks and temporary tattoos.

"The project gives the same experience to kids who can't have candy. Having those options opens it up to all children to have fun," Shelby said.

The Teal Pumpkin Project has a national map of participating homes.

When Shelby finds trick-or-treaters at her door, she asks if any of the goblins have allergies or other reasons for needing a nonfood treat. She has two bowls ready one with candy and one with trinkets.

She often finds kids with no dietary restrictions are just as interested in a toy because they've gathered so much candy already.

Shelby goes to a party store to buy bags of trinkets. In many ways, they are better to hand out to everyone dietary restrictions or not, she said. Candy doesn't keep year to year. Plastic trinkets do.

The same is true for the kids. Candy gets gobbled quickly. Toys, crayons and other nonfood treats last much longer.

For families that deal with Type I diabetes, Shelby shared many tips for trick-or-treating.

"Plan ahead first and foremost," she said. "Sit down with your child and make a plan for Halloween night and school parties."

The joint plan needs to be shared with anyone the child comes in contact with so friends and family can help support the plan.

Children with diabetes should have a healthy dinner with protein before treat-or-treating because it can help buffer blood sugars.

Shelby recommends knowing the carbohydrate counts of common candies. Parents can find an online list at beyondtype1.org.

Children with diabetes or food allegies should wear a medical ID bracelet when they trick-or-treat with friends.

"Make a new tradition," Shelby said. "Make lower carbohydrate Halloween treats and have a party at home rather than trick-or-treating."

Link:
Halloween is tricky time for kids with food allergies, diabetes - Grand Haven Tribune

HAMILTON, Ontario, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Reliq Health Technologies Inc. (TSXV:RHT or OTCQB:RQHTF) (Reliq or the Company), a technology company focused on developing innovative mobile health (mHealth) and telemedicine solutions for Community Healthcare, today announced that it has partnered with leading US Diabetes Care company Smart Meter LLC. (Tampa, FL) to provide Reliqs iUGO CARE Remote Patient Monitoring (RPM) and Chronic Care Management (CCM) solutions to patients coping with diabetes and other chronic conditions.

The iGlucose blood glucose meter is compact, portable, user friendly and cellular-enabled, so its an excellent fit for rural and remote diabetes patients who may not have conventional internet access, as well as for active diabetics who need a glucose meter that they can take with them wherever they go, said Dr. Lisa Crossley, CEO of Reliq Health Technologies, Inc. Integrating with the iGlucose meter allows us to offer our clients innovative new options for managing diabetes in the community. The partnership with Smart Meter also fits our new Call Centers business model. Reliqs Call Center in Port St Lucie, FL is focused on implementation of our iUGO CARE Remote Patient Monitoring (RPM) and Chronic Care Management (CCM) solution with patients, physicians and payors. The resources of the Call Center will facilitate enrollment and support patients and their healthcare providers. Not only will the Call Center offer paid support services to our clients, we have also secured commitments from partners, including Smart Meter, to utilize our contract outreach and engagement services. As a result, the Call Center will be self-funding and profitable from day one.

Were excited to partner with Reliq Health to offer their advanced technology platform to our enterprise clients, said Mr. Brahim Zabeli, CEO of Smart Meter LLC. Smart Meter has relationships with clinicians and disease management companies, and we look forward to helping these providers reduce costs and improve patient care through our partnership with Reliq. Combining our iGlucose meter and cost-effective test strips, and Reliqs iUGO CARE platform to support caregiver workflows, automatically collect key patient health data and connect residents to physicians through virtual visits, will create new revenue models for residential care, increase profits and enhance patient and family satisfaction. We are also pleased to be able to leverage Reliqs Call Center for outreach and engagement to expand our client base.

About Smart MeterSmart Meter, LLC is the innovator of iGlucose; a simple, convenient and affordable solution addressing todays challenges in the monitoring and management of diabetes. The game-changer is cellular technology, which allows patients to just test, letting iGlucose seamlessly share patient data. Providers, in real time, now receive comprehensive, powerful, reliable data, allowing for individualized care and targeted population health management. iGlucose is a simpler, quicker path to improve outcomes, lower costs and access new sources of reimbursement through remote patient monitoring. To find out more about how iGlucose is simply doing the unimaginable through Better Data, Better Care, Better Outcomes, visit http://www.iglucose.com.

About Reliq HealthReliq Health Technologies is a healthcare technology company that specializes in developing innovative software solutions for the Community Care market. Reliqs powerful iUGO CARE platform supports care coordination and community-based healthcare. The iUGO CARE platform integrates wearables, sensors, voice technology and intuitive mobile apps and desktop user interfaces for patients, clinicians and healthcare administrators. iUGO CARE allows complex patients to receive high quality care at home, improving health outcomes, enhancing quality of life for patients and families and reducing the cost of care delivery. iUGO CARE provides real-time access to remote patient monitoring data, allowing for timely interventions by the care team to prevent costly hospital readmissions and ER visits. Reliq Health Technologies trades on the TSX Venture under the symbol RHT and on the OTCQB as RQHTF.

ON BEHALF OF THE BOARDDr. Lisa CrossleyCEO and Director

For further information please contact:Investor Relations at ir@reliqhealth.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward Looking InformationCertain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are "forward-looking statements".

We caution you that such "forward-looking statements" involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements.

Forward-looking statements include, but are not limited to, statements with respect to commercial operations, including technology development, anticipated revenues, projected size of market, and other information that is based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management.

Reliq Health Technologies Inc. (the "Company") does not intend and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, technology development and marketing activities, the Company's historical experience with technology development, uninsured risks. Actual results may differ materially from those expressed or implied by such forward-looking statements.

SOURCE: Reliq Health Technologies Inc.

#406A 175 Longwood Rd SHamilton, ON, L8P 0A1Phone: (888) 869-1362Fax: (647) 317-1929

Continue reading here:
Reliq Health Technologies, Inc. Partners with Leading US Diabetes Care Company to Deliver RPM/CCM Solutions - GlobeNewswire

NEW YORK CITYLife insurance company John Hancock is teaming up with VerilyLife Sciences to offer a life insurance solution anddigital wellness program to help people with diabetes manage and improve their condition.

The new product, John Hancock Aspire, isa unique collaboration between the Boston-based life insurer and Verily, the healthcare division of Google parent company Alphabet,and will leverage the capabilities of Onduo, a virtual diabetes clinic.

Onduo is ajoint venture between Verily and drugmaker Sanofi.that was spun off in 2016 and now partners with health insurers like Blue Cross Blue Shield to provide chronic care management toplan members with diabetes. Onduo also is collaborating with Walgreens on a virtual diabetes and medication adherence solution for the company's employees.

Like this story? Subscribe to FierceHealthcare!

The healthcare sector remains in flux as policy, regulation, technology and trends shape the market. FierceHealthcare subscribers rely on our suite of newsletters as their must-read source for the latest news, analysis and data impacting their world. Sign up today to get healthcare news and updates delivered to your inbox and read on the go.

RELATED:Blue Cross Blue Shield Association partners with Google affiliate for diabetes care pilot

Through the collaboration with Verily and Onduo, John Hancock is offering consumers living withdiabetes a life insurance plan combined witha technology-enabled wellness program that provides coaching, clinical support, education and rewards designed to help manage and improve their health. Plan members have the potential to save up to 25% on their premiums, according to the company.

Qualifying John Hancock Aspire customers with Type 2 diabetes will get access toOnduo's virtual clinic, which includes blood glucose monitoring devices paired with the Onduo app, and will be connected to Onduo's virtual care team forpersonalized guidance and support.

During an event in Manhattan Monday to announce the new partnership, Andy Conrad, Verily's CEO, said it was a "daring" collaboration that presented an opportunity to scale up Onduo's virtual diabetes clinic.

"Through this initiative, Verily and John Hancock are pushing the envelope on the role life insurance can play in both providing financial security and helping people live longer, healthier lives," Conrad said.

"This is a great opportunity to do this at scale and in a clever, thoughtful and different way," he said.

Brooks Tingle, president and CEO of John Hancock Insurance, said his industry hasn't traditionally served people living with diabetes well.

"We're actually among the most uniquely positioned to help improve their health outcomes because our customer relationships often last a lifetime," he said.

RELATED:Walgreens and Verily announce partnerships for diabetes, medication adherence

Tingle told FierceHealthcare the company saw an opportunity to work with a leading technology company to leverage a personalized approach to disease management and make life insurance more personalized and engaging.

"There are wonderful solutions out there and wanted to take those andplug them into alife insurance policy. We're trying to make life insurance as much about living as dying," he said.

"The organizations that will have the greatest impact on healthcare will be companies like Google," Tingle said. "These companies are making significantinvestments to use technology and analytics to improve health outcomes."

Google's work with Verily was driven by a desire to do "world-changing projects," Conrad said. "In areas like healthcare, we wanted to change the paradigm from an episodic perspective to prevention." The collaboration with John Hancock fits into that mission, he noted.

The two companies could potentially expand the partnership to other chronic diseases such as hypertension or depression, Conrad said.

For John Hancock Insurance, the more than30 million Americans living with diabetes represent a sizable market opportunity. Half of those consumers either don't have enough life insurance or don't have any life insurance coverage at all, according to data from the Centers for Disease Control and Prevention.

Diabetes remains the seventh leading cause of death inthe U.S., with 1.5 million Americans diagnosed every year, according to the American Diabetes Association.

Former emergency medicine physician Joshua Riff, M.D., now CEO of Onduo, said he joined the Verily-Sanofi joint venture because he saw firsthand the toll of chronic disease on patients.

RELATED:Alphabet's Verily collaborating with Atrius Health, Palo Alto VA on population health projects

The majority of patients he saw in the emergency roomhad some form of chronic disease or complications due to their disease, he said. "Why are they coming to see me? When I would ask, I would hear the same story. Patients would say'I have a hard time getting to my doctor.''I only see my doctor a few times a year, but I live with this disease 365 days a year andI have no support or guidance.'"

Onduo's platform was developed to transform how chronic care is delivered, Riff said, with a focus on health monitoring and tracking, personalized guidance andaccess to care teams. "It's designed to support people where they are and on their terms," he said.

"It's rare to be a part of something where all the incentives are aligned," Jessica Mega, M.D., chief medical officer at Verily, told FierceHealthcare. She noted that the program provides incentives and rewards that support consumers' financial health and physical health and well-being. And Onduo's technology platform uses data to tailor guidance and support to each patient, she said.

"The fact that the medical community is now embracing this is important. We're empowering patients to help them make healthier choices," she said.

Verily, originally Google Life Sciences, once part of Google X,spun outin 2015 to lead Alphabets healthcare and life sciences research. The company has beenquietly expanding its footprint in the world of healthcare and collaborating with health systems and other providerson initiatives to tackle major healthchallenges.

The company recently announced it was teaming up with Atrius Health and the Palo Alto Veterans Affairs healthcare system to improve patient outcomes through population health initiatives.

The rest is here:
Verily, John Hancock collaborating on life insurance solution that offers virtual diabetes management - FierceHealthcare

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced presentation of real-world data from pediatric users of the t:slim X2 insulin pump with Basal-IQ predictive low-glucose suspend technology at the 45th annual conference of the International Society for Pediatric and Adolescent Diabetes (ISPAD). Data from 2,696 users under the age of 18 years old showed an overall rate of hypoglycemia of only 0.9 percent when using Basal-IQ technology. A subgroup of users with at least 21 days of sensor-augmented pump data prior to use of Basal-IQ technology demonstrated a 31 percent reduction in hypoglycemia following introduction of the feature (n=491).

Data Highlights

The study included de-identified real-world data uploaded to Tandems t:connect web application between August 31, 2018 and March 14, 2019, which was retrospectively analyzed to assess hypoglycemia outcomes.

Overall Group (n=2,696) The overall rate of hypoglycemia (defined as percent median time spent with sensor readings <70 mg/dL or 3.9 mmol/L) for this group was 0.9 percent. Algorithm-enabled insulin suspensions occurred on average 4.9 times per day for an average 15.5 minutes per suspension.

Subgroup (n=491) Pre-post analysis demonstrated median time spent <70 mg/dL or 3.9 mmol/L decreased from 1.6 to 1.1 percent upon introduction of Basal-IQ technology (p = <0.001), representing a 31 percent reduction in hypoglycemia. Sensor time-in-range (defined as 70-180 mg/dL or 3.9-10.0 mmol/L) remained steady between pre- and post-Basal-IQ technology use, however, there was a significant decrease in sensor glucose values greater than 300 mg/dL or 16.7 mmol/L (p=0.007).

About the t:slim X2 Insulin Pump with Basal-IQ Technology

The simple-to-use t:slim X2 insulin pump with Basal-IQ predictive low glucose suspend technology uses glucose values from an integrated Dexcom G6 continuous glucose monitor to predict and help prevent lows with zero fingersticks*. The t:slim X2 insulin pump includes advanced features like a large color touchscreen, rechargeable battery, Bluetooth wireless technology, USB connectivity and watertight construction (IPX7)1. It is capable of remote software updates using a personal computer, offering the potential for in-warranty users to access new features as they meet necessary regulatory requirements2. The t:slim X2 insulin pump is up to 38 percent smaller than other insulin pumps and holds up to 300 units of insulin.3

Launch of the t:slim X2 insulin pump with Basal-IQ technology has begun in select international geographies. It is currently available on new t:slim X2 insulin pumps and as a software update to all in-warranty t:slim X2 insulin pump users in the United Kingdom, Sweden, Denmark, Spain, Italy, the Czech Republic, and South Africa.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandems flagship product, the t:slim X2 insulin pump, is capable of remote software updates using a personal computer and features integrated continuous glucose monitoring. Tandem is based in San Diego, California.

Tandem Diabetes Care, t:connect, and Basal-IQ are registered trademarks, and t:slim X2 is a trademark of Tandem Diabetes Care, Inc. Dexcom and Dexcom G6 are registered trademarks of Dexcom, Inc. The Bluetooth wordmark is a registered trademark owned by Bluetooth SIG, Inc. and any use of such mark by Tandem Diabetes Care, Inc. is under license. All other third-party marks are the property of their respective owners.

Important Safety Information for the t:slim X2 Insulin Pump with Basal-IQ Technology

Federal (USA) law restricts this device to sale by or on the order of a physician. The t:slim X2 insulin pump with Basal-IQ technology (the System) consists of the t:slim X2 insulin pump, which contains Basal-IQ technology, and a compatible CGM. CGM sold separately. The t:slim X2 insulin pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The t:slim X2 insulin pump can be used solely for continuous insulin delivery and as part of the System. When the System is used with a compatible iCGM, Basal-IQ technology can be used to suspend insulin delivery based on CGM sensor readings. The System is indicated for use in individuals 6 years of age and greater. The System is intended for single patient use and requires a prescription. The System is indicated for use with NovoLog/NovoRapid or Humalog U-100 insulin. The System is not approved for use in pregnant women, persons on dialysis, or critically ill patients. The pump is not intended for anyone unable or unwilling to: use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see their healthcare provider regularly. The user must also have adequate vision and/or hearing to recognize all functions of the pump, including alerts. For detailed indications for use and safety information, visit tandemdiabetes.com/safetyinfo.

Forward Looking Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements relate to, among other things, the ability of the t:slim X2 pump to provide remote feature updates, the timing and outcome of regulatory approvals for new product features and updates, and the ability of our products to improve customer satisfaction and clinical outcomes. These statements are subject to numerous risks and uncertainties, including the risks that technical problems may prevent or delay remote software updates, regulatory agencies may fail to approve new product features or updates on our expected timeframe or at all, and the level of customer satisfaction from the use of our products and features may be different from what we expect, as well as other risks identified in Tandems most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, respectively, and other documents we file with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events or other factors.

* If glucose alerts and CGM readings do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions. Dexcom G6 CGM sold separately.

1 Tested to a depth of 3 feet for 30 minutes2 Additional feature updates are not currently available for the t:slim X2 insulin pump with Basal-IQ technology and are subject to future FDA approvals. A prescription and additional training may be required to access certain future software updates.3 38 percent smaller than MiniMed 630G and 670G and at least 28 percent smaller than MiniMed 530G, Animas Vibe and Omnipod System. Data on file, Tandem Diabetes Care.

Read this article:
Tandem Diabetes Care Presents Positive Real-World Data from Pediatric Users of t:slim X2 Insulin Pump with Basal-IQ Technology at International...

Green advocacy groups, mostly based in Europe, are the single biggest impediment to sustainable agriculture, said GLP executive director Jon Entine in an interview with Marcel Bruins, editorial director of European Seed magazine and website.

CRISPR and other gene-editing and New Breeding Techniques are fast being adopted around the world, although many environmental activist groups are doing their best to frighten the public and intimidate legislators into erecting insurmountable regulatory barriers. Theyve been largely successful in Europe, which is blocking gene-edited crops under legislation passed in the pre-CRISPR era in 2001, Entine said, but the rest of the world is more open to the innovations.

Entine was interviewed in mid-October at the annual Euroseeds Congress 2019, held in Stockholm.

The GLP founder raised a range of challenges facing agriculture in the face of what can only be called a determined anti-technology faction. Africa appears to be emerging as a central battleground. Europe has strong historical trade and cultural ties to the continent. It has long used those connections to push its anti-GMO policies. Africa is now rebelling, Entine noted, and is pursuing biotechnology innovation led by African scientists, particularly focusing on animal biotech, in an attempt to shed Europes yoke.

Its an uphill battle for Europe and Africa, Entine noted. Activist groups, mostly from European nations, are going door-to-door, telling Africans deliberate falsehoods about biotechnology, claiming that genetically engineered crops cause cancer and sterility.

Entine went on to offer a communications strategy to give the science a chance, so crop biotechnology has an opportunity to succeed on its merits, without being tangled in Europes ideological web.

Jon Entine is the founder and executive director of the Genetic Literacy Project. Twitter: @jonentine.

Read more:
Video: 'Blood on their hands'Greens' resistance to biotechnology blocks sustainable agriculture, climate change innovation, says GLP's Jon Entine -...

In attendance at the Park Hyatt Hotel in Midtown Manhattan, were approximately 140 guests, predominately from the US, but also from across Europe, the Middle East, Asia as well as Australia. Partners Capital's client base of investment professionals, institutional clients and family offices were all represented. This included investment committee members from New York University School of Law, the Los Angeles Museum of Contemporary Art, Singapore educational endowments and INSEAD Business School.

The afternoon started with Stan Miranda, Chief Executive Officer of Partners Capital, describing the overarching theme of the Client Workshop being de-globalization, with four underlying sub-themes - geopolitics, China, biotechnology and impact investing. "While Globalization has been a strong force in the past, lifting people out of poverty and bringing the world closer together, there are serious headwinds. Given these headwinds, we face a question of whether investors should concentrate their investments more domestically or seek opportunities out of new economic alliances that are likely to form?" The afternoon provided arguments on multiple sides.

Internal speakers were joined by three experts:

Matthew Gertken, Geopolitical Strategist at BCA Researchspoke on geopolitics' impact on investment strategy going forward. BCA research concludes that the US will be in at least a decade-long economic "cold war" with China. Any trade deals between now and Trump's re-election will be temporary stop-gaps distracting investors from the real changes in the form of deeper alliances between China and its historical and new allies; and between the US and its historical allies.

Jason Tan, Chief Investment Officer from Jeneration Capitallaid out the facts surrounding the technology arms race between China and the US, highlighting the very different strategies Chinese tech leaders are following versus US tech leaders. These companies initially start with one online business and subsequently expand into additional segments (e.g., content & media, social & messaging, mobile payments), funding start-ups to create new innovations so they do not have to themselves. The integrated ecosystem approach is highlighted by the fact that China is home to a disproportionate number of the "super" unicorns ($15B+ valued companies).

Behzad Aghazadeh, Managing Partner at Avoro Capitalspoke on the future biotechnology breakthroughs saying that "today we are benefitting from the groundwork of decades of research that can now be widely applied to medicine.breakthroughs in cancer are accelerating as we continue to see advances in treatments for previously uncurable indications. Today there are 16,000 ongoing pipeline projects, up from 6,000 in 2001, which provides a strong platform of ongoing innovation in the sector".Stan Miranda added his own comments on investing in the public biotech sector - "There are 1,200 public biotech companies today, only 5% of which have revenue and 75% have not yet reached phase III drug trials. By investing with firms like Avoro, we expect to see venture capital like returns from this liquid public sector of the public equity markets."

Partners Capital presentations included two four-person panel sessions featuring the Partners Capital CIO's and Asset Class Heads, addressing Client Portfolio Strategy Choices and Asset Class Strategies going forward, respectively.

- Will Fox, Partner, Head of North America, Boston - spoke on the right illiquidity budget

- John Collis, Partner, Head of Europe, London spoke on tactical asset allocation

- Elizabeth Trotta, Managing Director, New York covered our recession playbook

- David Shushan, Partner, Boston discussed technology sector over-weights

- Alex Band, Managing Director, Head of Public Equities, Boston

- Rich Scarinci, Partner, Absolute Return & Credit, Boston

- Suzanne Streeter, Partner, Head of Private Markets, Boston

- Emma Bewley, Principal, Private Debt, London

The audience responded most to Elizabeth Trotta's run-through of the "Partners Capital Recession Playbook", which is already in place in most client portfolios. But the key message of the internal presentations was how Partners Capital believes that a highly diversified, risk-managed multi-asset class portfolio is the best long term defense against an economic downturn.

The afternoon's final session, Impact Investing, featured a short video of Sir Ronald Cohen, filmed specifically for the event, addressing the importance of social impact investing and why investors should be focusing not only on risk and return but also on optimizing the impact of their investments on society and the environment. Euan Finlay, Partner and Chair of Partners Capital's Responsible Investing Committee, then went on to discuss the firm's responsible investing framework for implementing and reporting on responsible investing in client portfolios.

Paul Dimitruk, Chairman of Partners Capital, closed the day focusing on the firm's desire to be not just an advisor, but a "thought-partner" on each client's investment journey. He implored each client to continue to challenge and push Partners Capital to be the best it can be. "Our mission is to do go beyond just asset allocation and manager selection, but to help discern where risk and return are, and where value is created or destroyed."

About Partners Capital

Founded in 2001, Partners Capital is a wholly independent Outsourced Investment Office (OCIO) primarily serving sophisticated institutions and senior investment professionals inEurope,North AmericaandAsia. With offices inBoston,New York,San Francisco, London, Singapore and Paris, the firm is one of the few truly global OCIOs, employing 175 people worldwide and covering all major asset classes. The firm oversees assets of more than$27 billion. Its institutional clients include a number of Oxford and Cambridge Colleges,Eton College, INSEAD business school, the Research Foundation for theState of New York'sUniversity System, the Royal Academy of Arts, Milton Academy, the Hong Kong Cancer Fund and the Cancer Research Institute. Additional information on Partners Capital may be found athttp://www.partners-cap.com.

Photo: https://mma.prnewswire.com/media/1019263/Partners_Capital_AIW_Image.jpg Logo: https://mma.prnewswire.com/media/817400/Partners_Capital_Logo.jpg

SOURCE Partners Capital

Home

See the rest here:
Partners Capital Shines the Spotlight on Geopolitics, China, Biotechnology and Impact Investing at Its Fourth Annual Investor Workshop - PRNewswire

Biotechnology Market will expand at +9.9% CAGR to hit $775 Billion by 2025

Biotechnology For example, growth in this area is expected to accelerate as the proliferation of conditions such as hepatitis B disease and other problems increases. The growing population in the United States, China, and India is expected to increase the importance of these products due to growing interest in livelihood and horticultural items such as wheat, rice, sugar cane, and soybeans. In addition, factors such as water shortages, low yields, insect attacks and limited access to farmland require scientists to participate in extensive R & D.

The organization has partnered with members of the industry to focus on strengthening and using the unique system. In conjunction with the Government Grants Foundation and various self-governing communities, significant associations will improve funding to support R & D and new product improvement attempts for biotechnology funding.

U.S. biotechnology market dominated North America region in 2017 and will continue to project similar trend with +11.1% CAGR during analysis timeframe.

Ask for sample copy of this report at:

https://healthcareintelligencemarkets.com/request_sample.php?id=128077

Top key player profiled in this report:Agilent Technologies, BioGen Medical Instruments, Danaher, F. Hoffmann-La Roche, Abbott Laboratories Illumina, Merck, PerkinElmer, Qiagen and Thermo Fisher Scientific, Amgen, Bio-Rad Laboratories.

The analysis further includes a thorough description based on the dominant competitors that illuminate plant location, capacity, technology development, price structure, value chain, manufacturing methodology, sales / distribution network, raw materials and import and export activities. It also reveals participants financial stability and provides a detailed assessment of their revenue model, sales volume, profit margin and annual growth rate.

Get Expected Discount on this report:https://healthcareintelligencemarkets.com/ask_for_discount.php?id=128077

Today, North America leads the market for Biotechnology, followed by Europe due to the potential of Biotechnology. Emerging economies in Asia Pacific, Latin America, the Middle East and Africa are also expected to grow rapidly in these developing countries as the need for Biotechnology grows.

Technology Outlook (Revenue, USD Billion; 2014 2025)

DNA Sequencing

Nanobiotechnology

Tissue engineering and Regeneration

Fermentation

Cell Based Assay

PCR Technology

Chromatography Market

Others

Application Outlook (Revenue, USD Billion; 2014 2025)

Health

Food & Agriculture

Natural Resources & Environment

Industrial Processing

Bioinformatics

Others

Major factors covered in the report:

Enquiry before buying: https://healthcareintelligencemarkets.com/enquiry_before_buying.php?id=128077

About Us:

At HealthCare Intelligence Markets

Contact Us:

Address: 90, State Office Center,

90, State Street Suite 700,

Albany, NY 12207

Email: sales@healthcareintelligencemarkets.com

Web: http://www.healthcareintelligencemarkets.com

Phone: +1 (888) 616-2766

Read this article:
Astonishing Growth in Biotechnology Market 2019: Insights of the Industry & Rising Demand by Top Companies like Agilent Technologies, BioGen...

The market study on the global Biotechnology Reagent market will encompass the entire ecosystem of the industry, covering five major regions namely North America, Europe, Asia Pacific, Latin America and Middle East & Africa, and the major countries falling under those regions. The study will feature estimates in terms of sales revenue and consumption from 2019 to 2025, at the global level and across the major regions mentioned above. The study has been created using a unique research methodology specifically designed for this market.

(Halloween Special Discount Offer for Limited Period)Add this report toCART and Use Coupon Code HALLOWEEN40 to avail 40% Instant Discounthttps://inforgrowth.com/report/5610186/biotechnology-reagent-market

Quantitative information includes Biotechnology Reagent Market estimates & forecast for a upcoming years, at the global level, split across the key segments covered under the scope of the study, and the major regions and countries. Sales revenue and consumption estimates, year-on-year growth analysis, price estimation and trend analysis, etc. will be a part of quantitative information for the mentioned segments and regions/countries. Qualitative information will discuss the key factors driving the restraining the growth of the market, and the possible growth opportunities of the market, regulatory scenario, value chain & supply chain analysis, export & import analysis, attractive investment proposition, and Porters 5 Forces analysis among others will be a part of qualitative information. Further, justification for the estimates for each segments, and regions will also be provided in qualitative form.

Request a Sample of Biotechnology Reagent Market Research Report and Analysis of Key Players at https://inforgrowth.com/sample-request/5610186/biotechnology-reagent-market

Major players profiled in the report are Abbott Laboratories, Agilent Technologies, Beckman Coulter, BD Medical, Roche Diagnostics, Thermo Fisher Scientific, Merck Millipore, GE Healthcare, Perkinelmer, Tosoh Corporation, Siemens Healthcare, Biomerieux, Sigma Aldrich, Lonza Group, Life Technologies, Quality Biological, Bio-Rad Laboratories, Hoefer.

On the basis of products, report split into, Biotechnology Reagent.

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including Protein Synthesis & Purification, Gene Expression, DNA & RNA Analysis, Drug Testing, Other.

The study will also feature the key companies operating in the industry, their product/business portfolio, market share, financial status, regional share, segment revenue, SWOT analysis, key strategies including mergers & acquisitions, product developments, joint ventures & partnerships an expansions among others, and their latest news as well. The study will also provide a list of emerging players in the Biotechnology Reagent market.

The global Biotechnology Reagent market is bifurcated on the basis of types and on the basis of distribution channel.

Based on regions, the market is classified into North America, Europe, Asia Pacific, Middle East & Africa and Latin America. The study will provide detailed qualitative and quantitative information on the above mentioned segments for every region and country covered under the scope of the study.

Furthermore, this study will help our clients solve the following issues:

This study will address some of the most critical questions which are listed below:

Ask Your Queries or Requirements at https://inforgrowth.com/enquiry/5610186/biotechnology-reagent-market

About InForGrowth:

We are a market-intelligence company formed with the objective of providing clients access to the most relevant and accurate research content for their growth needs. At InForGrowth, we understand Research requirements and help a client in taking informed business critical decisions. Given the complexities and interdependencies of market-intelligence, there is always more than one source to explore and arrive at the right answer. Through our smart search feature and our reliable & trusted publishing partners, we are paving way for a more simplified and relevant research.

Contact:Mr. RohanEmail:[emailprotected] US: +1-909-329-2808 UK: +44-203-743-1890

Continued here:
News Live 2019: Global Biotechnology Reagents Market Rise to High Globally In Next Five Years - Maxi Wire

How far can we go with DNA? The scientific community does not yet have the answer, as the potential of this molecule seems infinite. But to study the possibilities offered in this field, laboratories must still have enough material for researchers to continue their work.

However, for the past forty years, DNA has been manufactured by chemical synthesis. A particularly long and costly process, with an error rate that increases as the sequence lengthens.

In this context, researchers are looking to develop alternatives to synthesize DNA more easily, with more convincing results. Among the solutions considered, one that particularly appealed to the scientific community: enzymatic synthesis. This process, which is faster and more efficient, and for which it is no longer necessary to be a chemist, is now used for the production of medicines, perfumes, cosmetics and biofuels.

The synthetic DNA market is estimated at $1.5 billion, with a growth of 10% per year. The French start-up DNA Script is developing a printer based on genetically modified enzymes to generate a personalized DNA sequence in a few hours. To make synthetic DNA a lever for predictive medicine, but not only, the company raised 11 million in September 2017. And also, an additional 35 million in May.

Founded in 2014 by Thomas Ybert, Sylvain Gariel and Xavier Godron, DNA Script has developed a printer capable of synthesizing high-quality DNA to foster innovation in science and technology. Through this technology, DNA Script intends to give a second wind to the writing of genetic codes.

The new process developed by the company makes it possible to produce better quality and longer DNA molecules. This process is donde in a much shorter time frame than usual production methods. And provides an opportunity for researchers in molecular biology to accelerate their experiments to achieve faster results.

These advances should eventually make it possible to develop new therapeutic products, such as medicines or vaccines. But also to move towards more ecological production of chemicals or to propose a new way of storing data.

DNA Scripts printer could even take on a new dimension with Crispr-Cas9. A genome transformation technique that allows DNA modification by targeting a gene with unparalleled accuracy. To understand better, FrenchWeb went to meet Xavier Godron and Sylvain Gariel. Two of the three founders of the French start-up, in their laboratory at the Kremlin-Bictre, south of Paris.

__

(Featured Image bymadartzgraphics)

First published infrenchweb, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. B2I assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. B2I is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Read the original here:
How synthetic DNA is revolutionizing research in biotechnology - Born2Invest